Rectifying global inequities in neuromyelitis optica diagnosis and treatment.
Farrah J MateenPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
The standard of care for patients with neuromyelitis optica (NMO) has become highly unequal globally. Sufficient data have been published to demonstrate that NMO is a disabling-and at times, fatal-disease needing preventive immunosuppressive treatment. Since 2019, there are multiple regulatory authority-approved disease-modifying therapies (DMTs) for aquaporin-4 antibody seropositive NMO for patients. Reframing the picture of NMO globally is now needed. When considered as a disease of high mortality when left untreated, parallel programs to those for cancer, HIV/AIDS, or tuberculosis can be considered. Nine collective goals for rectifying global inequities in NMO diagnosis and treatment are proposed.
Keyphrases
- hiv aids
- ejection fraction
- antiretroviral therapy
- end stage renal disease
- healthcare
- newly diagnosed
- papillary thyroid
- public health
- type diabetes
- palliative care
- human immunodeficiency virus
- transcription factor
- mycobacterium tuberculosis
- cardiovascular events
- chronic pain
- hepatitis c virus
- hiv infected
- big data
- coronary artery disease
- patient reported outcomes
- systematic review
- squamous cell
- risk factors
- young adults
- quality improvement
- artificial intelligence
- global health
- health insurance